Regeneron Pharmaceuticals First Quarter 2026 Financial Results

The provided documents consist of Regeneron Pharmaceuticals' first-quarter 2026 financial report and a corresponding press release detailing the company’s operational performance. Revenues reached $3.6 billion, a 19% increase driven largely by Dupixent sales and the successful launch of EYLEA HD, which recently received expanded FDA dosing approval. The materials outline significant corporate milestones, including the introduction of Otarmeni, a pioneering gene therapy for genetic hearing loss that the firm intends to distribute for free. Management also highlights a new $3.0 billion share repurchase program and a strategic agreement with the U.S. government aimed at lowering drug prices for domestic patients. Despite strong top-line growth, the reports note a slight decline in GAAP net income due to higher research and development investments and temporary manufacturing disruptions. Finally, the sources detail ongoing legal challenges, specifically patent litigation and antitrust proceedings regarding several of their core pharmaceutical products.